Dyax Readies HAE Therapy Kalbitor For Launch; Awareness Precedes Approval

Despite still awaiting FDA approval, Dyax is gearing up for the launch of its hereditary angioedema agent Kalbitor (ecallantide), focusing mainly on awareness and reimbursement issues

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet